DiagnoCure Furthers Development of Diagnostic Pipeline

    New Data Regarding Shc Prognostic Tests Presented in October 1st issue of
    Clinical Cancer Research

    QUEBEC CITY, Nov. 7 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
specialty laboratory services, today announced the publication of new data
regarding one of its proprietary prognostic tests for breast, colon and
potentially other cancers.
    The October 1st issue of Clinical Cancer Research states that measuring
p66 Shc tumor levels provides a unique and simple tool for stratifying stage
IIA colon cancer patients by risk of recurrence and disease-specific death and
may assist in determining treatment strategies for these patients. The study
included 240 chemotherapy patients with stage IIA colon cancer. An analysis of
p66 Shc scores was found to be a significant prognostic indicator of
relapse-free survival. DiagnoCure intends to conduct additional validating
clinical studies.
    "These study results confirm that DiagnoCure's acquisition of the Shc
tests in August 2007 was directly in line with our strategic goal of creating
a suite of high-value tests that will aid in the diagnosis, prognosis/staging
and ultimately treatment decisions for patients with cancer" said John
Schafer, President and CEO of DiagnoCure.
    The Shc tests have the added potential to guide physician treatment
decisions when used in conjunction with the Company's GC-C-based tests for
colorectal cancer, acquired earlier in 2007 and scheduled to launch from the
Company's CLIA-certified laboratory in 2008.

    About Shc proteins

    The potential clinical value of tests for Shc proteins have been studied
extensively in multiple clinical studies involving patients with five tumor
types, including breast and colon. Results have shown the tests to be strong
indicators for a patient's risk of disease recurrence, as well as predictors
of response to certain cancer therapies, such as tamoxifen or traditional
chemotherapy. The tests measure the level of Shc proteins in tumor specimens
removed during surgery. The Shc proteins are involved in a number of
well-documented cellular pathways that are correlated with tumor
aggressiveness across many types of cancer, offering a broad opportunity for
clinical testing. The study published in Clinical Cancer Research was led by
Dr. Steven Grossman, of the University of Massachusetts, and Dr. A. Raymond   
Frackelton Jr., Ph.D., of the Roger Williams Medical Center of Providence,
Rhode Island.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering lab services that increase
clinician and patient confidence in making critical treatment decisions.
DiagnoCure is currently preparing to launch the first GC-C-based molecular
test for the management of colorectal cancer. In 2003, the Company entered
into a strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the development
and commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary genetic marker highly specific to prostate cancer. The test is now
available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward- looking statements regarding
the outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Jean-Pierre Trudel & Associates: Jean-Pierre
Trudel, ARP, (514) 347-6111, jp.trudel@videotron.ca; DiagnoCure Inc.: 
communications@diagnocure.com; Jean-Pierre Trudel & Associates is now working
with DiagnoCure for its investors relations

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890